Effectiveness and Safety of Semaglutide in Type 1 Diabetes: A Danish Nationwide Cohort Study (2018–2024)
Puriya Daniel Würtz Yazdanfard, Vanja Kosjerina, Hannah Karin Wood-Kurland, Mikkel Porsborg Andersen, Eva Hommel, Thomas Fremming Dejgaard, Kirsten Nørgaard, Christian Torp-Pedersen, Kathrine Kold Sørensen · 2026
Read Effectiveness and Safety of Semaglutide in Type 1 Diabetes: A Danish Nationwide Cohort Study (2018–2024) by Puriya Daniel Würtz Yazdanfard, Vanja Kosjerina, Hannah Karin Wood-Kurland, Mikkel Porsborg Andersen, Eva Hommel, Thomas Fremming Dejgaard, Kirsten Nørgaard, Christian Torp-Pedersen, Kathrine Kold Sørensen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13208826.txt.
Description
Puriya Würtz Yazdanfard and co-authors study Danes with type 1 diabetes who started semaglutide, a drug approved for type 2 disease and weight care. Use in type 1 is rising without approval, driven by weight and glucose hopes. Safety worries include dangerous lows and ketoacidosis.
National registries found the starters and matched each to four similar non-users. Follow-up ran up to two years. Glucose paths were modeled over time, and hospital visits for lows and ketoacidosis were compared. Sticking with the drug was also tracked, with death handled properly in the math. Nationwide data can catch harms trials miss. Off-label use earns a real-world verdict here.
Catalog record
| CREATOR | Puriya Daniel Würtz Yazdanfard, Vanja Kosjerina, Hannah Karin Wood-Kurland, Mikkel Porsborg Andersen, Eva Hommel, Thomas Fremming Dejgaard, Kirsten Nørgaard, Christian Torp-Pedersen, Kathrine Kold Sørensen |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |